Less Frequent IV Dosing & Tumor Microenvironment (TME) Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy and in Combination With Pembrolizumab (ARTISTRY-3)

NCT04592653 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

78

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumor

Interventions

BIOLOGICAL: Nemvaleukin alfa
BIOLOGICAL: Pembrolizumab

Sponsor

Mural Oncology, Inc